Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Temozolomide + Toca FC + Vocimagene amiretrorepvec |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Toca FC | DB107-FC|DB107FC | Chemotherapy - Antimetabolite 14 | Toca FC (DB107-FC) is an extended release form of flucytosine, which inhibits DNA synthesis after conversion to 5-fluorouracil (PMID: 30676111). | |
Vocimagene amiretrorepvec | T5.0002|Toca 511|DB107-RRV | Chemotherapy - Antimetabolite 14 | Vocimagene amiretrorepvec (DB107-RRV) is a retroviral vector encoding yeast cytosine deaminase, which converts the prodrug flucytosine into 5-fluorouracil upon infection of tumor cells, potentially leading to tumor cell death (PMID: 22547150, PMID: 30676111). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06504381 | Phase Ib/II | Toca FC + Vocimagene amiretrorepvec Temozolomide + Toca FC + Vocimagene amiretrorepvec | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Not yet recruiting | USA | 0 |